Imaging on lung cancer and treatment with targeted therapy

The identification of genetic mutations known as oncogenic driver mutations that lead to the growth and survival of cancer cells has been an important advance in the field of oncology. Treatment in advanced non-small cell lung cancer (NSCLC) has transitioned from a more general approach to a more personalized approach based on genetic mutations of the cancer itself. Common mutations detected in patients with advanced NSCLC include mutations of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK).

from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2F5SnRO